IL-6 Blockade Enhances the Efficacy of CDK4/6 Inhibitor in <i>BRCA1</i>-Mutant Triple-Negative Breast Cancer Cells.

ABSTRACT: Breast cancer gene 1 (BRCA1) is a tumor suppressor gene essential for DNA repair, and its mutations are linked to aggressive breast cancers with poor prognosis. While poly (ADP-ribose) polymerase (PARP) inhibitors benefit some patients with BRCA1-mutant, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, issues such as limited efficacy and drug resistance persist. This is especially critical for triple-negative breast cancer (TNBC), which lacks targeted therapies. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors such as abemaciclib-FDA-approved for estrogen receptor (ER)-positive/HER2-negative breast cancer-are emerging as potential treatments for TNBC. We evaluated abemaciclib in BRCA1-mutant TNBC cell lines (SUM149, HCC1937, and MDA-MB-

SUBMITTER: Pan L 

PROVIDER: S-EPMC12564161 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature